Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
183.23B
Market cap183.23B
Price-Earnings ratio
26.70
Price-Earnings ratio26.70
Dividend yield
2.76%
Dividend yield2.76%
Average volume
2.71M
Average volume2.71M
High today
$346.30
High today$346.30
Low today
$338.95
Low today$338.95
Open price
$343.99
Open price$343.99
Volume
3.43M
Volume3.43M
52 Week high
$346.38
52 Week high$346.38
52 Week low
$253.30
52 Week low$253.30

Stock Snapshot

Amgen(AMGN) stock is priced at $340.16, giving the company a market capitalization of 183.23B. It carries a P/E multiple of 26.70 and pays a dividend yield of 2.8%.

As of 2025-12-04, Amgen(AMGN) stock has fluctuated between $338.95 and $346.30. The current price stands at $340.16, placing the stock +0.4% above today's low and -1.8% off the high.

Amgen(AMGN) shares are trading with a volume of 3.43M, against a daily average of 2.71M.

In the last year, Amgen(AMGN) shares hit a 52-week high of $346.38 and a 52-week low of $253.30.

In the last year, Amgen(AMGN) shares hit a 52-week high of $346.38 and a 52-week low of $253.30.

AMGN News

Simply Wall St 22h
Will Strong Q3 Beat And Pipeline Updates Change Amgen's Future Earnings Narrative?

In late November 2025, Amgen reported stronger-than-expected Q3 results, lifted by very large Repatha sales growth, solid contributions from Prolia and rare dis...

Will Strong Q3 Beat And Pipeline Updates Change Amgen's Future Earnings Narrative?
Benzinga 1d
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday. Analyst Lachlan Hanbury-Brown writes that the company's anti-IGF-1R...

Simply Wall St 5d
Is Now the Right Time to Revisit Amgen After Its Recent 18% Price Surge?

Wondering if Amgen is a hidden gem or already fully priced? You’re not alone. Now might be the perfect time to take a closer look at its value. Amgen’s stock h...

Is Now the Right Time to Revisit Amgen After Its Recent 18% Price Surge?

Analyst ratings

45%

of 33 ratings
Buy
45.5%
Hold
45.5%
Sell
9.1%

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.